ASCO 2025: What’s New for MBC?
In our Season 11 opening episode, we’re bringing you the latest updates from the 2025 ASCO Annual Meeting on metastatic breast cancer. Dr. Ashley Schreier, breast oncologist at Weill Cornell Medicine, breaks down key research and explains what it could mean for people living with MBC.
Topics include:
Research results for hormone therapy options like camizestrant
The role of ESR1 mutation testing
Results from treatment combinations like Enhertu and Perjeta, and Trodelvy and Keytruda
How to navigate clinical trial access
Tips for staying hopeful while exploring treatment options
Whether you’re a patient, caregiver, or advocate, this episode is packed with insights to help you stay informed and empowered.
Meet the Guest of the Episode
Dr. Ashley Schreier
Dr. Schreier is an Assistant Professor of Medicine within the Division of Hematology and Medical Oncology at Weill Cornell Medicine. She treats patients with all forms of breast cancer and has a special interest in caring for those with triple negative breast cancer (TNBC), which has been the emphasis of her research. Dr. Schreier received her B.S. in 2012 from Cornell University. She then entered medical school at NYIT College of Osteopathic Medicine followed by residency in Internal Medicine at the Albert Einstein College of Medicine/Montefiore Medical Center and fellowship in Hematology and medical Oncology at Weill Cornell. She has been an attending here since 2023 and works as a clinician in breast medical oncology and is also an active clinical and translational investigator.
